Intensity Therapeutics, Inc. (INTS) bonds
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.28+0.19 (+6.15%)
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Intensity Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Intensity Therapeutics's 10-K for the period ended Nov 30, 2022
| Issue | Coupon |
|---|---|
| 2021 Convertible Note Convertible at $12 a share | 3.00% |
| 2022 Convertible Note Convertible | 10.00% |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.
See a number that looks wrong?